Boston Red Sox ace Garrett Crochet had a close call Sunday when a liner skipped off his glove and nose on its way to second base for a groundout. Red Sox manager Alex Cora rushed to the mound with ...

Garrett Crochet avoided a potentially serious injury with quick reflexes. The Boston Red Sox pitcher was clipped in the nose by a line drive in the fourth inning of Sunday's 5-4 loss to the ...

Red Sox starting pitcher Garrett Crochet allowed a lead-off home run to Byron Buxton to open Sunday's game, and his roller coaster outing continued after a Carlos Correa line drive drilled him in ...

Viking Therapeutics is developing drugs for obesity and non-alcoholic fatty liver disease. The company has no revenue and may have none for several years as it works to get drug approval. Viking ...

If the Red Sox could draw up the ideal game, it would probably look a lot like Tuesday night’s 10-2 series opener victory in Toronto. They received seven innings from their new ace, Garrett ...

Viking Therapeutics (NASDAQ:VKTX) and other developers of oral weight loss drugs traded sharply higher on Tuesday after Pfizer (NYSE:PFE) CEO Albert Bourla indicated plans to seek deals to add ...

After Garrett Crochet made his Fenway Park debut during the season’s first homestand amid frigid conditions, he was frustrated. He owned a 1.45 ERA at the time through three starts, but he felt ...

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (NASDAQ: VKTX), the turbulence has been extremely challenging thus far.

The Boston Red Sox and ace left-handed starter Garrett Crochet have agreed to a six-year contract extension, the team announced Tuesday. The contract is worth $170 million and begins with the 2026 ...

Obesity upstart Viking Therapeutics has agreed to pay a total of $150 million through 2028 to enlist CordenPharma for production of its dual GIP/GLP-1 agonist VK2735. Under the deal, CordenPharma ...